Suehirotake use for ME Patients to increase energy

September 23, 2008

I recently started taking a mushroom called Suehirotake. I read that there

have been studies done with its use with CFS, and patients with chronic

fatigue syndrome showed significant improvement accompanied by increased NK

cell counts, but I cannot find much. Traditional Chinese medicine

practitioners also use it to combat fatigue. I think it is working because

recently I went to the zoo with relatives walking around with intermittent

resting on the benches and spent the whole day, Later I was able to go out

to dinner. While I was very tired and vegged the next day, I did not crash.

Normally, I do not have that amount of energy for walking around. I

usually, can only walk around for about an hour

I cannot find much on it. Pubnet has nothing. I wanted to know if anyone

had any experience with it or knew anything about it. Below is some info I

found on immunesupport about a drug in trials that is derived from it

[Moderator: Often it is helpful to find the latin name for the more uncommon

items. I found that it was " Schizophyllum commune Fries " and got 15 hits on

medline, which lead me to the name of one of it's components " sizofiran (SPG) "

which gave me 202 hits. One example...

" These results indicate that SPG is able to modulate both cellular and humoral

immune responses specific for nucleocapsid antigens in patients with chronic

hepatitis B. " PMID: 1761362

I will leave you to review and extract items of note..]

Sizofiran - Sizofiran, an immunostimulant extracted from suehirotake

mushroom (Schizophyllum commune) cultured fluid, is under development by

Fidia Farmaceutici Italiani Deriviate Industriali a Affini for the potential

treatment of cancer and hepatitis B. Sizofiran is licensed by Kaken

Pharmaceutical Co., Ltd., Japan. Trials were underway for the treatment of

gastric and lung tumor; phase III trials are underway for the treatment of

hepatitis B; and the compound is in phase II trials for chronic fatigue

syndrome. By August 1999, Kaken was preparing its NDA filing for hepatitis

B.

Significant sizofiran-induced rises in IFN-gamma and IL-2 in culture medium

of phytohemagglutinin (PHA) or concanavalin A-stimulated peripheral blood

mononuclear cells have been observed. Further reports on sizofiran should

become available in the near future.

Recommended Posts